Cerenis lands $65M for mid-stage cholesterol drug program

Cerenis Therapeutics has nailed down $51.5 million in the first close of its Series C round, fueling the developer's mid-stage clinical trial for its lead cholesterol therapy and positioning the biotech for a potential regulatory submission in a little more than two years. Cerenis and Novasep, a contract manufacturer, simultaneously announced €10.7 million in funding from the French government for the lead drug program.  

The latest round brings back a familiar group of venture backers which have contributed a total of $138 million in the company, which was launched by a group of Esperion Therapeutics execs and is based in Ann Arbor and France. And Crain's Detroit Business reports that a second close of the Series C could come later this year.

Cerenis lead drug is CER-001, an experimental therapy for boosting levels of 'good' cholesterol, a tonic for cardiovascular and metabolic diseases. The biotech's international research teams believe that CER-001 has the potential to rapidly regress atherosclerotic plaque.

In the latest round €20 million came from the Fund for Strategic Investment with an additional €20 million coming from the existing investors: Sofinnova Partners, HealthCap, Alta Partners and TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment. Jean-Pierre Garnier, former CEO of GlaxoSmithKline, will join the Cerenis board of directors as a non-executive director and will be FSI's representative on the board.

- see Cerenis' release on the latest round
- here's a release on the French government's support
- read the story from Crain's Detroit Business on the latest round

Suggested Articles

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.